Amyloidosis Treatment Market Size & Growth Forecast 2027–2036, By Segments (End-use, Treatment), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Amyloidosis Treatment Market size was worth USD 6.6 billion in 2026 and is expected to grow at a 7.03% CAGR between 2027 and 2036, crossing USD 13.02 billion by 2036. The industry revenue for 2027 is assessed at USD 6.99 billion.

• Base Year Value (2026): USD 6.6 billion
• CAGR (2027-2036): 7.03%
• Forecast Year Value (2036): USD 13.02 billion
• Historical Data Period: 2022-2026
• Largest Region: North America
• Forecast Period: 2027-2036

Amyloidosis Treatment Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America held a 41.72% share in 2026, supported by established diagnostic pathways, broad specialist care access, and coordinated referral networks that enable earlier treatment adoption.
  • Asia Pacific is projected to grow at an 8.48% CAGR as rare disease awareness improves, specialty care expands, and greater diagnosis and treatment access increase therapy adoption across the region.

• Segment Momentum:

  • Hospitals & Clinics held a 52.33% share in 2026 due to their ability to provide coordinated diagnosis, specialist oversight, infusion-based therapies, and multidisciplinary management for complex amyloidosis care.
  • Transplantation is growing fastest as specialized centers expand capabilities and pursue more intensive treatment approaches for carefully selected patients, supporting stronger long-term disease management outcomes.

• Market Expansion Drivers:

  • FDA-approved RNA-silencing therapy reducing transthyretin production in ATTR cardiomyopathy patients.
  • Oral transthyretin stabilizer improving treatment convenience and expanding ATTR-CM patient reach.
  • Expansion of multidisciplinary amyloidosis care centers strengthening coordinated diagnosis and long-term management.

• Leading Market Participants:

  Top companies in the amyloidosis treatment market include Pfizer Inc. (United States), Johnson & Johnson (United States), Takeda Pharmaceutical Company Limited (Japan), Bristol-Myers Squibb Company (United States), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), Sanofi S.A. (France), Alnylam Pharmaceuticals, Inc. (United States), Amgen Inc. (United States), GlaxoSmithKline plc (United Kingdom).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2026 Market Size: USD 6.6 billion
  • 2027 Estimated Market Size: USD 6.99 billion.
  • Projected Market Size: USD 13.02 billion by 2036
  • Growth Forecasts: 7.03% CAGR (2027-2036)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Hospitals & Clinics (End-use) | Chemotherapy (Treatment)
  • Emerging Opportunity Segment: Home Care Settings (End-use) | Transplantation (Treatment)

Market Growth Drivers and Industry Trends

FDA-approved RNA-silencing therapy reducing transthyretin production in ATTR cardiomyopathy patients

The availability of an FDA-approved RNA-silencing therapy that reduces transthyretin production is strengthening treatment options for patients with ATTR cardiomyopathy and will drive the amyloidosis treatment market by addressing an important underlying mechanism of disease progression. RNA-silencing approaches can reduce the production of transthyretin before the protein contributes to further amyloid accumulation, providing a disease-targeted therapeutic strategy rather than focusing solely on symptom management. Greater availability of an approved treatment option can also support physician adoption, improve therapeutic consideration for eligible patients, and encourage broader recognition of ATTR cardiomyopathy as a condition requiring targeted long-term intervention.

Oral transthyretin stabilizer improving treatment convenience and expanding ATTR-CM patient reach

Oral treatment options that stabilize transthyretin can improve convenience for patients and healthcare providers, supporting amyloidosis treatment market growth by making long-term disease management more accessible. An orally administered stabilizer can reduce dependence on administration settings associated with certain other treatment approaches and may fit more readily into routine patient care, particularly for individuals requiring sustained therapy. Improved convenience can also support treatment adherence and facilitate consideration of therapy among patients and clinicians, while an expanding therapeutic choice allows treatment strategies to be evaluated according to disease characteristics, patient needs, tolerability, and practical requirements for ongoing management.

Expansion of multidisciplinary amyloidosis care centers strengthening coordinated diagnosis and long-term management

The expansion of specialized multidisciplinary centers is improving coordination among the medical disciplines involved in identifying and managing amyloidosis, supporting growth of the amyloidosis treatment market through more structured patient care pathways. Amyloidosis can require collaboration among specialists responsible for cardiac evaluation, diagnostic testing, imaging, pathology, and therapeutic management, making coordinated expertise particularly important for appropriate disease recognition and treatment planning. Dedicated care centers can facilitate earlier referral, more consistent diagnostic assessment, treatment monitoring, and longitudinal follow-up, while concentrated clinical expertise can improve the ability of healthcare teams to manage complex cases and evaluate patients for available therapeutic approaches.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
FDA-approved RNA-silencing therapy reducing transthyretin production in ATTR cardiomyopathy patients	2.00%	High	North America, Europe	High	Near Term
Oral transthyretin stabilizer improving treatment convenience and expanding ATTR-CM patient reach	1.80%	High	North America, Europe, Asia Pacific	High	Near Term
Expansion of multidisciplinary amyloidosis care centers strengthening coordinated diagnosis and long-term management	1.50%	Moderate	North America, Asia Pacific	Medium	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

Holding the largest share of the amyloidosis treatment market, North America accounted for 41.72% in 2026, underpinned by advanced diagnostic capabilities, specialized treatment centers, and strong access to innovative therapies. Greater awareness of rare diseases and improvements in disease identification support earlier diagnosis and treatment, while established healthcare systems facilitate long-term management of complex amyloidosis conditions. Continued clinical research and investment in precision-oriented therapeutic approaches further strengthen the region's treatment infrastructure and overall market position.

Asia Pacific represents the fastest-growing region, supported by improving healthcare infrastructure, expanding access to specialized diagnostics, and rising awareness of rare and complex disorders. Greater investment in healthcare capacity is enabling more patients to receive appropriate evaluation and disease management, while improvements in medical education are increasing recognition of amyloidosis among healthcare professionals. Expanding access to advanced therapies and growing emphasis on specialized care are expected to strengthen regional adoption.

Key Country Insights

United States

Advanced Therapy Development

The U.S. amyloidosis treatment market is shaped by continued adoption of specialized therapies, diagnostic improvements, and coordinated care approaches. Healthcare providers are emphasizing earlier disease identification and access to targeted treatments, while pharmaceutical companies continue advancing therapeutic options for different amyloidosis forms.

Japan

Rare Disease Management

Japan is strengthening amyloidosis treatment practices through improved awareness, specialized medical centers, and advances in diagnostic methods. Healthcare stakeholders are focusing on timely identification and personalized management strategies to address disease progression and improve long-term patient outcomes.

South Korea

Precision Medicine Integration

South Korea’s amyloidosis treatment market is influenced by growing interest in precision healthcare and advanced diagnostic technologies. Medical institutions are prioritizing specialized treatment protocols, improved disease recognition, and access to newer therapies for patients with rare protein-related disorders.

Germany

Specialized Care Networks

Germany’s amyloidosis treatment market is supported by established clinical expertise and multidisciplinary approaches for complex rare diseases. Treatment priorities include improved patient pathways, specialized diagnostic capabilities, and integration of innovative therapies within hospital and specialty care settings.

France

Clinical Expertise Expansion

France is advancing amyloidosis treatment through specialized healthcare programs and improved management of rare conditions. Providers are focusing on multidisciplinary collaboration, diagnostic refinement, and the integration of innovative therapies to enhance care pathways for affected patients.

Italy

Rare Disease Care Optimization

Italy’s amyloidosis treatment market is shaped by efforts to improve specialized care delivery and patient monitoring. Healthcare systems are emphasizing coordinated treatment networks, diagnostic accuracy, and adoption of advanced therapies to address the complexities of amyloid-related diseases.

Segment Leadership and Growth Trends

 

End-use Segment Analysis: Hospitals & Clinics (Largest Segment) vs Home Care Settings (Fastest-Growing Segment)

The hospitals & clinics segment held the largest share of the amyloidosis treatment market at 52.33% in 2026, supported by the need for specialized diagnosis, multidisciplinary treatment, and continuous clinical monitoring. Amyloidosis management often requires coordinated care involving diagnostic evaluation, disease-specific therapies, supportive treatment, and monitoring of organ involvement, making hospitals and clinics central to treatment delivery. The availability of specialized healthcare professionals, advanced diagnostic infrastructure, and access to complex therapeutic interventions further reinforces demand within institutional settings.

Home care settings are gaining momentum as treatment approaches increasingly emphasize patient convenience, continuity of care, and reduced dependence on prolonged hospital visits. Greater availability of therapies and supportive care that can be administered or monitored outside institutional environments is encouraging a gradual shift toward decentralized management. Home-based care can also improve treatment accessibility for patients requiring ongoing disease management while reducing the logistical burden associated with frequent clinical visits, supporting stronger adoption of this setting.

Treatment Segment Analysis: Chemotherapy (Largest Segment) vs Transplantation (Fastest-Growing Segment)

In the amyloidosis treatment market, chemotherapy accounted for the largest share of 28.62% in 2026, reflecting its established role in managing disease by targeting abnormal plasma cells responsible for the production of amyloid-forming proteins. Its integration into established treatment protocols, broad clinical familiarity, and applicability across relevant patient populations continue to support utilization. Chemotherapy also remains an important component of treatment strategies where suppression of underlying disease activity is required, sustaining its position within the treatment landscape.

Transplantation is emerging as a rapidly advancing treatment approach, particularly for eligible patients requiring intensive intervention and long-term disease control. Improvements in patient selection, supportive care, and treatment management are strengthening the feasibility of transplantation within specialized clinical pathways. Increasing attention to disease modification and the pursuit of more durable therapeutic outcomes is also supporting greater consideration of transplantation, particularly in settings with advanced specialist capabilities.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
End-use	Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, Others	Hospitals & Clinics	Home Care Settings
Treatment	Chemotherapy, Immunosuppressive Drugs, Transplantation, Supportive Care, Surgery, Others	Chemotherapy	Transplantation

Competitive Landscape and Market Positioning

Leading companies in the amyloidosis treatment market:

1. Pfizer Inc. (United States)

2. Johnson & Johnson (United States)

3. Takeda Pharmaceutical Company Limited (Japan)

4. Bristol-Myers Squibb Company (United States)

5. Novartis AG (Switzerland)

6. F. Hoffmann-La Roche Ltd (Switzerland)

7. Sanofi S.A. (France)

8. Alnylam Pharmaceuticals Inc. (United States)

9. Amgen Inc. (United States)

10. GlaxoSmithKline plc (United Kingdom)

The amyloidosis treatment market is evolving through targeted therapeutic innovation aimed at addressing rare and complex disease mechanisms. Continuous clinical research is enhancing treatment precision and expanding available options. Collaborative development efforts are accelerating innovation cycles and improving patient-focused therapeutic outcomes.

Industry Development/News

Company Name	Date	Key Development
Protego Biopharma	Feb-26	The company closed an oversubscribed $130 million Series B financing round to accelerate the development of its lead AL amyloidosis candidate, PROT-001. This capital injection facilitates the transition of the asset into pivotal clinical trials, strengthening the company’s competitive position in the pipeline for disease-modifying therapies.
AstraZeneca	Feb-26	AstraZeneca and Ionis received a positive EU regulatory recommendation for Wainzua (eplontersen) for treating transthyretin amyloidosis with polyneuropathy. Based on Phase III NEURO-TTRansform trial data, the approval progress marks a critical expansion in commercial availability for this RNA-targeted therapy, aiming to address significant unmet needs in patients with hereditary disease.
GSK	Feb-26	Results from the global CARES Phase III program evaluating anselamimab in AL amyloidosis showed that the therapy did not meet the primary endpoint in the overall patient population. However, observed therapeutic signals in specific patient subgroups support ongoing evaluation, representing a nuanced development in the landscape for anti-fibril treatments targeting protein misfolding disorders.